With a focus on understanding the underlying caused of the disease - ss of insulin from beta cells - not just the symptoms, Fairbanks Pharmaceuticals is developing novel treatments for diabetes. Efforts of the firm organzie around facilitating repair of existing insulin-producing beta cells in the short term and regeneration of new beta cells in the longer term. In October 2018, the firm was awarded the 2018 Boston Innovation Prize by Boehringer Ingelheim which included a golden ticket to LabCentral.
